trending Market Intelligence /marketintelligence/en/news-insights/trending/4pbyye2j-44bolws_ldcxw2 content esgSubNav
In This List

SELLAS therapy secures US FDA orphan drug status to treat multiple myeloma

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


SELLAS therapy secures US FDA orphan drug status to treat multiple myeloma

SELLAS Life Sciences Group Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its medicine galinpepimut-S to treat multiple myeloma, a type of cancer that forms in the plasma cells.

The New York-based biopharmaceutical company said both the U.S. FDA and the European Medicines Agency have already granted orphan drug status for galinpepimut-S to treat acute myeloid leukemia, a type of blood cancer, and malignant pleural mesothelioma, a type of lung cancer.

Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved.